GleamWall
中文EN

JANX Janux Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1817713 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY132.9%
TTM net income YoY2.0%
TTM EPS YoY4.8%
Revenue 3-yr CAGR40.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-599.3%
Net margin-428.7%
FCF margin-232.6%
EBITDA margin-591.3%

Returns

ROE-10.6%
ROA-9.9%
ROIC (approx.)-12.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets7.3%
Debt / equity0.00x
Current ratio17.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$10.00M$10.59M
R&D expense$125.90M$68.39M
SG&A expense$41.77M$41.05M
Operating income-$157.67M-$98.85M
Income tax$0$0
Net income-$113.62M-$68.99M
EBITDA-$155.64M-$96.79M
EPS (basic)-1.83-1.28
EPS (diluted)-1.83-1.28
Weighted avg. shares (diluted)61.97M53.75M
Balance sheet
Cash & equivalents$52.33M$430.61M
Short-term investments$914.23M$594.57M
Receivables$0—
Current assets$975.89M$1.03B
PP&E, net$3.85M$4.86M
Total assets$1.00B$1.06B
Current liabilities$25.00M$17.46M
Total liabilities$44.74M$38.73M
Shareholders' equity$956.82M$1.02B
Shares outstanding60.38M59.06M
Cash flow statement
Operating cash flow-$82.23M-$43.81M
Capital expenditure$1.04M$359,000
Free cash flow-$83.28M-$44.17M
Investing cash flow-$300.98M-$258.02M
Financing cash flow$4.95M$713.24M
Depreciation & amortization$2.03M$2.06M
Stock-based compensation$40.22M$33.02M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.